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for treatment with dabigatran. It is assumed that all diagnosed AF patients eligible 
for oral anticoagulation currently receive warfarin and that all patients switch to 
dabigatran in Year 1, regardless of International Normalised Ratio (INR) control 
amongst warfarin patients. Differences in numbers of clinical events expected to 
occur based on a patient’s antithrombotic treatment were estimated by applying 
event rates from literature sources. Costs were estimated from a HSE perspective and 
included costs of clinical events, disability costs and medication costs. Results: 
A total of 28,332 Irish patients are estimated to have been diagnosed with AF and 
are eligible for dabigatran. Switching these patients from warfarin to dabigatran 
may avoid: 657 strokes; 792 major bleeds; 1,437 deaths. By Year 5, cumulative dabi-
gatran drug costs were estimated at € 7,670,870. Cost savings due to clinical events 
avoided amounted to € 2,894,743 and savings on disability costs at € 5,563,349, giving 
a total cost saving with dabigatran of € 787,223. ConClusions: Use of dabigatran 
as compared to warfarin for stroke prevention in AF in the Irish setting may avoid 
a significant number of clinical events and result in overall cost savings.
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objeCtives: To conduct a literature review on the economic burden of venous throm-
boembolism (VTE) (encompassing deep vein thrombosis (DVT) and pulmonary embo-
lism (PE)) and related complications. Methods: Eligible English-language studies 
published post-1990 were identified from electronic databases (Medline, EMBASE 
and Cochrane Library: accessed December 2012) and conference proceedings with 
no restriction on geographical location or patient population. All costs are reported 
in US$ adjusted to 2013 levels. Results: Twenty-nine studies met eligibility criteria: 
United States (n= 17), Canada (n= 2), Australia (n= 1), South America (n= 1) and Europe 
(n= 8). The estimated annual cost of VTE treatment is in excess of $2 billion in the 
USA and Europe and $153 million in Australia. This figure rises to $15.6–$34.8 billion 
in the US and to $1.78 billion in Australia on inclusion of complications, productivity 
loss and other societal costs. The cost of treating PE per patient ($12,567-$20,488) is 
higher than that of treating DVT ($2,912-$13,299). Hospitalisation is the main cost 
driver for VTE treatment, accounting for 56%-89% of all treatment costs. For patients 
with cancer, costs were 30-50% higher for those with VTE compared with those with-
out VTE. VTE-related complications incur additional costs including: bleeding (up to 
$23,963 per patient with a major bleed); recurrent VTE (up to $18,122 per patient); 
post-thrombotic syndrome (increase of up to 75% in treatment cost); chronic throm-
boembolic pulmonary hypertension (up to $6,708 per patient); and heparin-induced 
thrombocytopenia (up to $18,779 per patient). ConClusions: Incident VTE events 
and related complications are associated with significant economic burden across 
several patient populations. Treating PE may cost up to five times more than treating 
DVT, with hospitalisation reported as the major cost driver of VTE treatment. Effective 
and convenient therapies associated with both a reduced incidence of bleeding and 
complications are required to further reduce the cost burden associated with VTE.
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objeCtives: To assess the cost-effectiveness of actovegin and solcoseryl in the treat-
ment of Russian patients with acute ischemic stroke and predict potential budget 
impact of the implementation of actovegin in routine clinical practice. Methods: 
The pharmacoeconomic model was developed based on the data from Russian 
clinical trial performed by A. Fedin et al. (2000). Two groups of patients (100 persons 
each) hospitalized with acute ischemic stroke were included in the model. The first 
group of patients received conventional therapy + actovegin and the second group 
received conventional therapy + solcoseryl. Based on the reported by A. Fedin et al. 
time-dependent mortality reduction in actovegin-treated patients (mortality rate 
was 7% in patients started actovegin within the first 6 hours after stroke onset, 
10% – in those started actovegin within the first 24 hours, 14% – in those started 
actovegin after more than 24 hours, and it was much higher in the control group – 
21%) cost-effectiveness ratios (CERs) and indicator of economic rationality of costs 
of previous periods (IRPP) were calculated and compared. Results: Estimated CERs 
varied from 46,348.82 to 50,121.40 RUB per one survivor in the actovegin group and 
from 50,900.56 to 53,585.17 RUB per one survivor in the solcoseryl group. Inefficient 
expenditures (IRPP) varied from 301,730.83 RUB to 603,461.67 RUB in the actovegin 
group, and were 873,453.57 RUB in the solcoseryl group. ConClusions: The study 
has demonstrated the preferred cost-effectiveness profile of actovegin as compared 
to solcoseryl in patients with acute ischemic stroke.
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objeCtives: To assess the cost-effectiveness of citicoline in the treatment of Russian 
patients with acute ischemic stroke and identify potential budget impact of the imple-
mentation of citicoline in routine clinical practice. Methods: The pharmacoeco-
nomic model was developed based on the data of meta-analysis performed by A. 
Davalos et al. (2002). Two groups of 100 patients each were included in the model: the 
first group of patients received conventional therapy and the second group (active 
treatment group) additionally received citicoline. It was assumed that citicoline was 
given to patients in the active treatment group in the following way: during the first 
repeat procedure rates (TLR - target lesion revascularization) over 1 year. The model 
was developed from a Italian national health care system (NHS) perspective with 
a 5-year time horizon. A systematic literature review was carried out on TLR rates 
in patients with femoral-popliteal disease treated with one of the four treatment 
choices. Costs associated to each treatment are derived from the average DRG tariffs 
used for peripheral angioplasty procedures. A decision analytic model was devel-
oped to estimate total costs over 12 months of index procedures and possible revas-
cularizations. Results: Pooled 12-month TLR rates show clear patients benefit with 
DEB compared to PTA (8,6% vs 28,6%) and non-inferiority of DEB vs DES (9,4%) and 
BMS (11,5%). Total Italian DRG payments for index and repeat interventions (based 
on TLR rates estimation) across treatments showed that DEB was the least costly 
treatment strategy over 1 year, with saving of almost € 1,000 per patient with DEB 
vs PTA. Based on these per-patient savings, the potential total savings amounted 
to approximately € 2 million for an assumed annual increase of 5% in DEB adoption 
rate over 5 years. ConClusions: The analysis suggests clear patient benefit for 
DEB. Despite initial higher investments, DEB represents a cost-saving alternative 
to other technologies according to the NHS perspective.
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objeCtives: In Italy about 500,000 non-valvular atrial fibrillation (NVAF) patients 
have a major unmet medical need as they do not receive adequate anticoagulation 
therapy for stroke prophylaxis: many patients receive antiplatelet therapy, even 
when the guidelines recommend vitamin-K antagonists (VKA), or are not treated at 
all or have international normalized ratio inadequate control despite treatment with 
VKA. The purpose of this study was to perform a budget impact analysis of rivaroxa-
ban - a novel oral anticoagulant (NOAC) - in NVAF patients with the highest unmet 
medical need from the Italian health care system (SSN) perspective. Methods: 
Two scenarios were compared within a three-year timeframe: the actual scenario, 
where patients are treated according to current clinical practice (46% with VKA, 
38% with antiplatelets, 17% non-treated) and a scenario where Rivaroxaban is pre-
sent with increasing market shares. The event risks (ischemic and haemorrhagic 
stroke, systemic embolism, myocardial infarction and bleedings) were retrieved 
from the ROCKET-AF trial or from a network meta-analysis. Resource consumption 
was computed using mean regional tariffs. Since Rivaroxaban price is not officially 
published, the daily cost used ranges from € 2.10 (price of the first NOAC approved in 
this indication in Italy) and the lowest Rivaroxaban price available in Europe (€ 1.94). 
The results of the analysis are displayed as a total costs difference between the two 
scenarios. Results: A reduction in the total number of events and costs at SSN 
charge is shown since the first year from rivaroxaban introduction. The increase in 
pharmaceutical expenditure is offset by savings from a lower number of events to 
treat and absence of routine coagulation monitoring. ConClusions: The introduc-
tion of rivaroxaban in the national scenario is beneficial because it will provide a 
substantial reduction in the disease burden for patients and in costs for the SSN.
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ComPArison of dABigATrAn ETExilATE VErsus wArfArin, AsPrin & no 
TrEATmEnT for sTrokE PrEVEnTion in ATriAl fiBrillATion in EnglAnd, 
uniTEd kingdom, oVEr 5 yEArs
Sunderland T.J.1, Zah V.2, McCarron C.1
1Boehringer Ingelheim, Berkshire, UK, 2ZRx Outcomes Research Inc., Mississauga, ON, Canada
objeCtives: To estimate the number of clinical events and costs of these events 
for dabigatran etexilate (dabigatran) versus a combination of warfarin, aspirin and 
no treatment for stroke prevention in atrial fibrillation (AF) patients in an England, 
UK, setting over 5 years. Methods: An interactive model was built in Microsoft 
Excel to calculate the following: • Total number of AF patients eligible for dabi-
gatran • Number of clinical events for dabigatran, warfarin, aspirin and no treat-
ment patients over a 5 year time horizon. Clinical events included were stroke 
(ischaemic, haemorrhagic, systemic embolism); major bleeding (intracranial and 
extracranial); all cause mortality; acute myocardial infarction • Total costs of clini-
cal events for each treatment. The total cost per day for dabigatran is £2.20 per day; 
warfarin is £1.18; aspirin is £0.09; no treatment is £0.00. Warfarin had a TTR of 55% 
(from Jones et al 2005); aspirin and no treatment clinical event rates were from 
Roskell et al (2010). Dabigatran data was from the RE-LY trial Results: The model 
estimates there are 822,527 patients with AF in England, of which 78% are eligible 
for dabigatran (641,571). After 5 years, patients treated with dabigatran versus 80% 
with warfarin; 10% aspirin; 10% no treatment are associated with: 1) 27,357 fewer 
strokes (16,938 fewer ischaemic storkes); 2) 14,413 fewer major bleeding events; 
and 3) An increase of £268,167,861 in drug budget; however there is an overall cost 
saving of £11,240,201. The overall cost saving is predominantly driven by savings in 
disability following stroke. ConClusions: Study indicates that due to a superior 
clinical profile, dabigatran may more than offset the increase drug budgets, result-
ing in cost savings, if used preferentially versus warfarin, aspirin or no treatment.
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objeCtives: To estimate numbers of clinical events (strokes, major bleeds, acute 
myocardial infarctions and deaths) and health care costs over a five year period 
in Ireland following a switch of antithrombotic therapy for atrial fibrillation (AF) 
from warfarin to dabigatran. Methods: A model was built in Microsoft Excel and 
included an estimate of the number of Irish patients diagnosed with AF and eligible 
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the National Health Care system perspective. Results: Preoperative characteris-
tics and risk scores of the 2 groups were comparable. Hospital mortality was 3.7% 
in Sutured and 2.4% in Sutureless (p= 0.65). Aortic cross-clamp, cardiopulmonary 
bypass time and operation time were 20%, 23% and 16% shorter in Sutureless (each 
one p< 0.001).Sutureless required less blood transfusion (1.2±1.3 vs 2.5±3.7 units, 
p= 0.005) with a similar incidence of postoperative bleeding (2 patients vs 5, p= 0.221). 
Sutureless had a shorter intensive care unit stay (2.0±1.72vs 2.8±1.3 days, p< 0.001), 
a shorter hospital stay (11.4±3.9 vs 17.3±13.7 days, p< 0.001) and a shorter intuba-
tion time (9.5±4.6 vs 16.6±6.4 hours, p< 0.001). A neurological event was recorded in 
3 sutureless patients and in 6 sutures (p= 0.248). Sutured has an higher incidence 
of postoperative atrial fibrillation, pleura effusions and respiratory insufficiency (p 
0.015, 0.024 and 0.016, respectively). Reduced risk of post operative complication 
resulted in a dramatic reduction of resources consumption in the sutureless group 
allowing a saving of 50% of the complication related resource use. ConClusions: 
Shorter procedural times resulting from sutureless aortic valve replacement are 
associated with better outcomes and lower costs. Sutureless valve may be consid-
ered as the first-line treatment for patients underwent aortic valve replacement 
with a bioprosthesis.
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objeCtives: To assess the annual average costs and quality adjusted life years 
(QALYs) of stroke services in the UK before and after the introduction of the National 
Stroke Strategy (period: 2006-2011). Methods: Data from the South London Stroke 
Register (SLSR) from 2006 to 2011 were used to populate a discrete event simulation 
(DES) model. Parameters, such as daily probability of survival and length of stay, 
included in the model were calculated by using Cox proportional hazard model and 
multivariate regression methods respectively. Barthel Index was used as proxy for 
measures of quality of life. Treatment costs were introduced in the model in order 
to calculate the total costs based on resource usage. The model simulated the stroke 
care delivery from stroke onset with 10-year follow up. Average cost and QALYs 
were calculated for every year from 2006 to 2011. Results: The average total costs 
per treating a stroke patient decreased from £30,745 to £27,086 between 2006 and 
2011 (p-value for trend < 0.001). This is mainly as a result of savings achieved in the 
inpatient phase due to a shorter LOS and a higher proportion of patients with mild 
disability. Per patient QALY’s also increased from 2.2 to 3.1 during the same period 
(p-value for trend < 0.001), this is due to a higher proportion of patients having 
access to better organised stroke care. ConClusions: This study has demonstrated 
that stroke services in the UK have improved their value for money over time with 
constant gains in efficiency. The use of DES together with SLSR data allows the test-
ing of the costs and outcomes of a whole stroke provision system or components 
of it and provide opportunities for retrospective (as done in this study) as well as 
prospective analysis (in the case of health technology assessment studies).
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objeCtives: To assess the impact of a hypothetical increase in the stroke primary 
preventive care coverage in the UK. Productivity gains, using resource utilization 
as proxy, and monetary benefits were calculated. Methods: Data from the South 
London Stroke Register (SLSR) from 2009 to 2011 were used to create a hypothetical 
cohort to populate a discrete event simulation (DES) model. The model simulated 
the stroke care delivery from primary preventive stroke care until discharge from 
stroke unit or general medical ward. Primary preventive care was defined as taking 
medications to control hypertension, high-cholesterol and also anticoagulants in 
patients with atrial fibrillation in order to prevent strokes. Treatment costs were 
introduced in the model in order to calculate the total costs based on resource usage. 
Hypothetical scenarios consisting in 10% incremental increase of primary preven-
tive care for high-risk factors were tested. The reduction of strokes was given by 
relative risk reduction ratios extracted from clinical trials. Results: Our findings 
indicate that for every 10% increase in the number of patients undergoing primary 
prevention treatment the number of strokes would be reduced by 1.2%. In a scenario 
where 50% of the untreated patients receive primary prevention 7,232 strokes would 
be reduced per year. For the same scenario, 47 hyper acute beds, 359 acute beds and 
47 general medical ward beds could be saved in average. In total this would yield in 
£42.2 million of savings in the inpatient phase of stroke care. ConClusions: Our 
findings suggest that by enhancing primary prevention of stroke care in the UK, 
significant benefits can be achieved in terms of reductions in resource consumption 
and monetary savings as a result of averted strokes. The generation and analysis 
of these retrospective hypothetical scenarios, using real-world evidence on stroke, 
help evaluate policy choices in stroke care in the UK.
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objeCtives: Greater than 40% of Europeans over age 25 have hypertension, and 10% 
of those have medication resistant hypertension (RHT). In EU5 (France, Germany, 
Italy, Spain, UK) that results in 9.4 million persons with blood pressure above goal, 
despite treatment with 3+ medications. These patients have a greater than 30% 
risk of cardiovascular disease (CVD) over 10 years and an increased risk of end-
stage renal disease (ESRD). This analysis sought to quantify the burden of RHT 
10 days since acute stroke onset, 2,000 mg was administered intravenously; from day 
11 to the end of the treatment periods (74 days), 1,000 mg was administered per os. 
The time horizon adopted in the model was 12 weeks. Based on the data on effective-
ness of citicoline in complete patient recovery after 3 months reported by A. Davalos 
et al., the cost-effectiveness ratios (CERs) were calculated and compared. Results: 
Estimated CERs were 513,099.20 RUB per one patient recovered in control group and 
435,368.00 RUB per one patient recovered in citicoline group. Furthermore, the costs 
of rehabilitation of patients were lower in the citicoline group as compared to control 
group, cost savings were estimated to be about 1,719,610.00 RUB. ConClusions: The 
study has demonstrated that the treatment of acute ischemic stroke with citicoline 
was more cost-effective and had the potential to reduce the rehabilitation expenses.
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objeCtives: Heart failure (HF) is a costly disease imposing a substantial health 
burden which affects 1-2% of Europeans. Hospital readmission for HF is a common 
occurrence with 25% of all patients readmitted within 30-days following initial 
hospitalization. Reducing readmission is an important component of managing HF 
costs and increasingly being targeted with health care policy reforms. The objec-
tive of this study is to examine how remote patient monitoring (RPM) may affect 
health care costs following the placement of a CRT-D device for patients with HF 
through the use of a simulation model. Methods: The analysis was an individual 
patient event-based simulation from a US payer perspective based on a sample 
of patients from RAPID-RF, a multi-center prospective single-arm registry which 
enrolled 889 patients who received a CRT-D and RPM system (LATITUDE® Boston 
Scientific). The modeled population consisted of patients that had at least one alert 
for weight change, atrial tachycardia or ICD shock with a subsequent interven-
tion (N= 128). The population was limited to this subset to focus on the costs of 
changes in management due to RPM. A non-RPM control group was created by 
cloning each trial patient and simulating their response in the absence of RPM to the 
conditions that triggered each alert in the trial over one year using a decision tree 
which computed rates of hospitalization and physician contacts based on literature 
data. Event and hospitalization costs were estimated per Medicare (CMS) national 
average payment. Results: RPM reduced total costs after the index procedure by 
$323/patient driven by a reduction in costs related to hospitalization admissions. 
The decrease in hospital admission cost was partially offset by RPM’s increase in 
physician visits and telephone counseling. ConClusions: RPM has the potential 
to shift HF-related care from an inpatient setting to office-based care, resulting in 
cost savings to national payers.
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objeCtives: Analysis of cost containment of SSI via use of Dabigatran Etexilate 
(150MG) versus current standard of care (Warfarin) in prevention of stroke for non 
valvular atrial fibrillation patients in Turkish health care setting. Methods: All 
calculations are performed for a group of 1000 patients in each treatment arm per 
year (Treatment arms; Dabigatran 150MG & Warfarin 5MG – results are represented 
as “cost per patient per day”). Available clinical data is analyzed for calculation of 
event costs in each treatment arm (RE-LY study). Local costs of events are included 
from local literature. Microsoft Excel (2007) is used for calculations and construc-
tion of data tables. Results: Direct cost of SSI (indirect costs are not included in 
this analysis) is calculated in each treatment arm. Difference of daily medication 
cost between Dabigatran Etexilate and Warfarin treatments is +3.12 TL/Day*Patient 
however, this difference is calculated as -3.34 TL/Day*Patient when medication 
cost is combined with total treatment cost (costs of thromboembolic&adverse 
events, INR monitoring, impairment). Dabigatran Etexilate offers a cost contain-
ment (saving) of 0.22 TL/Day*Patient in prevention of stroke for non valvular atrial 
fibrillation patients in Turkish health care setting. ConClusions: Limitation of 
this study is covering only direct cost data due to lack of local literature on indirect 
costs. Further analysis may be performed by non-interventional studies, which 
will define cost containment data via real life cost and effectiveness values. This 
study demonstrates that Dabigatran Etexilate treatment may sustain cost contain-
ment (saving) via reduction of direct cost of SSI with respect to current standard of 
care, in prevention of stroke in patients with atrial fibrillation in current Turkish 
health care system.
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objeCtives: New sutureless aortic valve prostheses reduce the surgical time. 
Objective of this study is to asses if shorter operative times may also result in 
improved patient outcomes and the impact on the hospital costs. Methods: 
Records of 547 patients that underwent aortic valve replacement with a biopros-
thesis from March 2009 and May 2013 were identified. Based on a propensity score 
analysis 2 groups (Sutureless and Sutured) with 82 matched pairs were created from 
the 112 patients received a Perceval sutureless bioprosthesis and the 435 patients 
received a sutured valve. Hospital and follow up outcomes, resources consumption 
was recorded and compared between groups. Analysis was performed according 
